Industry

Life Sciences Tools & Services

Suppliers of instruments, reagents and contract research for biotech and pharma R&D. Stable demand from growing research budgets; switching costs and proprietary tech provide defensibility.

Total Companies
238
Company Intrinsic Valuation Profitability Score Solvency Score Market Cap
Thermo Fisher Scientific Inc
NYSE:TMO
Loading...
4% Overvalued
52 / 100
54 / 100
$191.8B
Danaher Corp
NYSE:DHR
Loading...
13% Overvalued
50 / 100
70 / 100
$144.2B
Samsung Biologics Co Ltd
KRX:207940
Loading...
39% Overvalued
57 / 100
87 / 100
$55.6B
Lonza Group AG
SIX:LONN
Loading...
12% Undervalued
50 / 100
53 / 100
$46.4B
WuXi AppTec Co Ltd
SSE:603259
Loading...
Fairly Valued
62 / 100
84 / 100
$38B
Agilent Technologies Inc
NYSE:A
Loading...
3% Overvalued
57 / 100
72 / 100
$33.9B
Waters Corp
NYSE:WAT
Loading...
42% Overvalued
61 / 100
78 / 100
$30.7B
IQVIA Holdings Inc
NYSE:IQV
Loading...
33% Undervalued
54 / 100
30 / 100
$29.5B
Mettler-Toledo International Inc
NYSE:MTD
Loading...
20% Overvalued
50 / 100
68 / 100
$26.8B
Illumina Inc
NASDAQ:ILMN
Loading...
7% Overvalued
53 / 100
61 / 100
$20.1B
Sartorius Stedim Biotech SA
PAR:DIM
Loading...
22% Overvalued
45 / 100
50 / 100
$19.5B
WuXi Biologics (Cayman) Inc
HKEX:2269
Loading...
1% Undervalued
53 / 100
96 / 100
$18.3B
Divi's Laboratories Ltd
NSE:DIVISLAB
Loading...
49% Overvalued
56 / 100
99 / 100
$18.2B
West Pharmaceutical Services Inc
NYSE:WST
Loading...
13% Overvalued
55 / 100
96 / 100
$18.1B
Eurofins Scientific SE
PAR:ERF
Loading...
21% Undervalued
48 / 100
45 / 100
$13.8B
Medpace Holdings Inc
NASDAQ:MEDP
Loading...
18% Overvalued
72 / 100
65 / 100
$13.1B
R
Revvity Inc
NYSE:RVTY
Loading...
6% Undervalued
47 / 100
46 / 100
$10.8B
Qiagen NV
NYSE:QGEN
Loading...
6% Overvalued
53 / 100
69 / 100
$10.3B
T
Tempus AI Inc
NASDAQ:TEM
Loading...
22% Overvalued
33 / 100
38 / 100
$9.3B
Bio-Techne Corp
NASDAQ:TECH
Loading...
17% Overvalued
50 / 100
86 / 100
$9B
Load More
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett